142 related articles for article (PubMed ID: 11728835)
1. Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate.
Marder SR; Aravagiri M; Wirshing WC; Wirshing DA; Lebell M; Mintz J
Schizophr Res; 2002 Jan; 53(1-2):25-30. PubMed ID: 11728835
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
4. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
Miller RS; Peterson GM; McLean S; Westhead TT; Gillies P
J Clin Pharm Ther; 1995 Apr; 20(2):55-62. PubMed ID: 7650075
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
6. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
7. Costs and benefits of two doses of fluphenazine.
Marder SR; Van Putten T; Mintz J; McKenzie J; Lebell M; Faltico G; May PR
Arch Gen Psychiatry; 1984 Nov; 41(11):1025-9. PubMed ID: 6437365
[TBL] [Abstract][Full Text] [Related]
8. Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression.
Gitlin MJ; Nuechterlein KH; Mintz J; Fogelson D; Bartzokis G; Ventura J; Subotnik K; Aravagiri M
Psychopharmacology (Berl); 2000 Mar; 148(4):350-4. PubMed ID: 10928306
[TBL] [Abstract][Full Text] [Related]
9. Fluphenazine decanoate: a clinical problem?
Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
[TBL] [Abstract][Full Text] [Related]
10. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
[TBL] [Abstract][Full Text] [Related]
11. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
Marder SR; Wirshing WC; Van Putten T; Mintz J; McKenzie J; Johnston-Cronk K; Lebell M; Liberman RP
Arch Gen Psychiatry; 1994 Apr; 51(4):280-7. PubMed ID: 8161288
[TBL] [Abstract][Full Text] [Related]
12. Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia.
McClelland HA; Farquharson RG; Leyburn P; Furness JA; Schiff AA
Arch Gen Psychiatry; 1976 Dec; 33(12):1435-9. PubMed ID: 11760
[TBL] [Abstract][Full Text] [Related]
13. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate.
Marder SR; Hawes EM; Van Putten T; Hubbard JW; McKay G; Mintz J; May PR; Midha KK
Psychopharmacology (Berl); 1986; 88(4):480-3. PubMed ID: 3085136
[TBL] [Abstract][Full Text] [Related]
14. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
15. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.
Marder SR; Van Putten T; Mintz J; Lebell M; McKenzie J; May PR
Arch Gen Psychiatry; 1987 Jun; 44(6):518-21. PubMed ID: 3555385
[TBL] [Abstract][Full Text] [Related]
16. Fluphenazine decanoate in acute and maintenance therapy of schizophrenia.
Altamura AC; Mauri MC; Guercetti G; Cazzullo CL
Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(5):613-23. PubMed ID: 3122268
[TBL] [Abstract][Full Text] [Related]
17. Fluphenazine plasma levels, dosage, efficacy, and side effects.
Levinson DF; Simpson GM; Lo ES; Cooper TB; Singh H; Yadalam K; Stephanos MJ
Am J Psychiatry; 1995 May; 152(5):765-71. PubMed ID: 7726317
[TBL] [Abstract][Full Text] [Related]
18. Patterns of plasma imipramine-desipramine concentrations in patients receiving concomitant fluphenazine decanoate.
Siris SG; Adan F; Lee A; Cooper TB; Mandeli J; Casey E
J Clin Psychiatry; 1988 Feb; 49(2):64-5. PubMed ID: 3338977
[TBL] [Abstract][Full Text] [Related]
19. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
Chouinard G; Annable L; Ross-Chouinard A
Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
[No Abstract] [Full Text] [Related]
20. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
